Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ALIA-1758
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : $1,400.0 million
Deal Type : Acquisition
AbbVie to buy Alzheimer's therapy developer Aliada Therapeutics for $1.4 bln
Details : AbbVie will acquire Aliada and it's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease.
Brand Name : ALIA-1758
Molecule Type : Large molecule
Upfront Cash : $1,400.0 million
October 28, 2024
Lead Product(s) : ALIA-1758
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : $1,400.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?